Oruka Therapeutics, Inc.
Developing long-acting antibodies targeting IL-23 and IL-17 pathways for psoriasis and related inflammatory diseases.
Immunology & inflammation · Long-acting monoclonal antibodies · Clinical (Phase 2)
Developing long-acting antibodies targeting IL-23 and IL-17 pathways for psoriasis and related inflammatory diseases.
Immunology & inflammation · Long-acting monoclonal antibodies · Clinical (Phase 2)